Whether negative symptoms are specified by category or across dimensions, discovering biomarkers to indicate specific treatment strategies is needed.
Dopamine D₂ antagonists impact nicotine reward processing in schizophrenia.
Researchers discovered that the mechanism of the gene SLC39A8 that is associated with schizophrenia can be manipulated with pharmacology, which has yet to be developed.
Researchers found that higher levels of grandiose delusions correlate with other symptoms, such as persecutory delusions and hallucinations.
Because the dopaminergic system is sexually dimorphic, researchers found that the same treatment compounds manifest differently for men and women with schizophrenia.
Valacyclovir was not efficacious in the study, perhaps because HSV-1 was in the dormant, nonactivated state and therefore non-responsive to valacyclovir effects.
Investigators sought to determine whether cognitive behavioral therapy is as effective as other psychosocial treatments for people with schizophrenia.
Study provides new evidence of a significantly elevated allostatic load even in the first 5 years of the illness course of schizophrenia spectrum disorders.
Study results showed that the prevalence of hypobetalipoproteinemia was 4-fold higher in the psychiatric group compared with the general population.
Researchers aimed to validate sleep deprivation and schizotypy as putative models of psychosis by replicating their effects on cognitive performance.
Psychosis, or a psychotic episode, is characterized by a distorted perception of reality that is often exacerbated by hallucinations or delusions.
The biomarkers of increased interleukin-6, IgA anti-lipopolysaccharide antibodies, and vitamin D deficiency “collectively may contribute to the inflammatory state in patients with psychosis.”
Although the new psychosocial intervention REFLEX was composed to address specific aspects of insight, its effects were not superior to that of simplified cognitive remediation training.
Study suggests that elaborating on specific self-defining memories is a valid therapeutic target and may be considered a tool to improve daily functioning in first episode psychosis.
The risk for very late-onset schizophrenia-like psychosis increases with age, migration, and traumatic life events.
Implementation intentions may have lasting beneficial effects in prospective memory and significant transfer effects to functional capacity in people with schizophrenia.
In schizophrenia, insight as rated by patients is not responsive to antipsychotic treatment, and should be considered a trait feature of the illness, according to new study.
Social decline may be an effective predictor of conversion outcome in clinically high-risk individuals.
The change in cognition in association with transition to psychosis along with the change in functioning was examined.
Investigators examined the neuroprotective effects of minocycline in patients with recent-onset psychosis and to replicate the therapeutic benefits of minocycline on negative symptoms.